Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
How we manage iron overload in sickle cell patients
source: British Journal of Haematology
year: 2017
authors: Coates TD, Wood JC
summary/abstract:Blood transfusion plays a prominent role in the management of patients with sickle cell disease (SCD), but causes significant iron overload. As transfusions are used to treat the severe complications of SCD, it remains difficult to distinguish whether organ damage is a consequence of iron overload or is due to the complications treated by transfusion. Better management has resulted in increased survival, but prolonged exposure to iron puts SCD patients at greater risk for iron-related complications that should be treated. The success of chelation therapy is dominated by patient adherence to prescribed treatment; thus, adjustment of drug regimens to increase adherence to treatment is critical. This review will discuss the current biology of iron homeostasis in patients with SCD and how this informs our clinical approach to treatment. We will present the clinical approach to treatment of iron overload at our centre using serial assessment of organ iron by magnetic resonance imaging.
organization: Keck School of Medicine, University of Southern CaliforniaDOI: 10.1111/bjh.14575
read more full text
+myBinderRelated Content
-
Edith Peterson Mitchell, MDEdith Peterson Mitchell, MD, is board ce...
-
SCDAA Gene Therapy Town Hall – Webinarhttps://www.youtube.com/watch?v=J77Gq9yI...
-
Today’s Faces of Sickle Cell Disease: Marqus ValentineWhen Marqus Valentine went to junior col...
-
Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chroni...Background: We undertook a large multisi...
-
Implementation of the NCAA sickle cell trait screening policy: A survey of athletic staff and student-athletesObjective: To describe the perspectives...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
Today’s Faces of Sickle Cell Disease: John Tisdale, MDFor many years, John Tisdale has been wo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.